Clinical trial
Aggrenox Prevention of Access Stenosis
NCT00067119 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH · Completed
Key facts
| NCT number | NCT00067119 |
|---|---|
| Title | Aggrenox Prevention of Access Stenosis |
| Official title | Effect of Dipyridamole Plus Aspirin on Hemodialysis Graft Patency |
| Acronym | GRAFT |
| Lead sponsor | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH |
| Collaborators | The Cleveland Clinic Boston University Duke University University of Iowa MaineHealth University of Texas Southwestern Medical Center University of Alabama at Birmingham Washington University School… |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Kidney Failure |
| Intervention type | Drug |
| Interventions | Aggrenox, Placebo |
| Enrollment | 649 |
| Start date | Jan 1, 2003 |
| Primary completion | Jan 31, 2008 |
| Completion | Jan 31, 2008 |
| First posted | Aug 13, 2003 |
| Last update posted | Sep 19, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: